Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Abstract Introduction Intraocular inflammation (IOI)-related adverse events (AEs) that may result in severe vision loss have been associated with the anti-vascular endothelial growth factor brolucizumab. In this study, we investigate the timing, management and resolution of IOI-related AEs in a larg...
Main Authors: | Ryan Zubricky, Jasmyne McCoy, Richard Donkor, David G. Miller, Nina Sonbolian, Andrew Heaney, Ver Bilano, Helene Karcher, Joseph M. Coney |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-06-01
|
Series: | Ophthalmology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40123-023-00741-w |
Similar Items
-
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
by: Justus G. Garweg, et al.
Published: (2023-01-01) -
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
by: Joseph M. Coney, et al.
Published: (2023-02-01) -
Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022-04-01) -
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022-04-01) -
Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
by: Sanjay Kumar Mishra, et al.
Published: (2022-07-01)